S. 3558 118th Congress
Prohibiting Foreign Access to American Genetic Information Act of 2024
- Government Operations and Politics
- Sponsor: Gary C. Peters
- Congress.gov ↗
Latest action, Sep 23, 2024: Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
10 cosponsors
Sponsored by Gary C. Peters (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
1 D · 9 R
- Democrat
- Republican
- Independent
Referred to: Senate: Homeland Security and Governmental Affairs Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
4 reports
4 reports
4 reports
4 reports
4 reports
ILLUMINA, INC.
AVENUE SOLUTIONS
4 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
CROSSROADS STRATEGIES, LLC
4 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
MARSHALL & POPP, LLC
4 reports
3 reports
3 reports
3 reports
WUXI BIOLOGICS USA LLC
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
3 reports
3 reports
All 25 of 33 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS, INC. | 4 | $1.1M | Q1 2024 | Q3 2024 | yes | |
| AMGEN INC | 4 | $11.6M | Q1 2024 | Q3 2024 | yes | |
| ASSOCIATION OF AMERICAN UNIVERSITIES | 4 | $245K | Q1 2024 | Q3 2024 | yes | |
| BATTELLE MEMORIAL INSTITUTE | 4 | $970K | Q1 2024 | Q3 2024 | yes | |
| BIOGEN | 4 | $4.1M | Q1 2024 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | $6.7M | Q1 2024 | Q3 2024 | yes | |
| ILLUMINA, INC. | AVENUE SOLUTIONS | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | CROSSROADS STRATEGIES, LLC | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | MARSHALL & POPP, LLC | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 3 | $3.9M | Q1 2024 | Q3 2024 | yes | |
| IGM BIOSCIENCES, INC. | 3 | $240K | Q1 2024 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 3 | $23.4M | Q1 2024 | Q3 2024 | yes | |
| TAKEDA PHARMACEUTICALS AMERICA INC | 3 | $2.5M | Q1 2024 | Q3 2024 | yes | |
| WUXI BIOLOGICS USA LLC | FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| WUXI BIOLOGICS USA LLC | 3 | $295K | Q4 2024 | Q3 2024 | yes | |
| BGI SHENZHEN CO., LTD. | STEPTOE LLP | 2 | $370K | Q4 2023 | Q1 2024 | yes |
| FUJIFILM HOLDINGS AMERICA CORPORATION | AKIN GUMP STRAUSS HAUER & FELD | 2 | $0 | Q4 2024 | Q3 2024 | yes |
| FUJIFILM HOLDINGS AMERICA CORPORATION | CGCN GROUP, LLC | 2 | $0 | Q4 2024 | Q3 2024 | yes |
| FUJIFILM HOLDINGS AMERICA CORPORATION | 2 | $485K | Q4 2024 | Q3 2024 | yes | |
| HARVARD UNIVERSITY--PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2 | $340K | Q4 2024 | Q2 2024 | yes | |
| WITH HONOR ACTION, INC. | 2 | $80K | Q1 2024 | Q2 2024 | yes | |
| AMGEN USA INC. | MARSHALL & POPP, LLC | 1 | $0 | Q1 2024 | Q1 2024 | yes |
| BROWN UNIVERSITY | 1 | $70K | Q4 2024 | Q4 2024 | yes | |
| CHAMBER OF COMMERCE OF THE U.S.A. | 1 | $23.4M | Q1 2024 | Q1 2024 | yes | |
| DANAHER CORPORATION | 1 | $180K | Q1 2024 | Q1 2024 | yes |